Apr 10 |
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
|
Apr 1 |
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
|
Mar 28 |
Top 5 Health Care Stocks That May Plunge In March
|
Mar 27 |
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 27 |
Neuronetics wins FDA clearance for device to treat adolescents with depression
|
Mar 25 |
Neuronetics gets FDA nod for NeuroStar as add-on treatment for adolescents with depression
|
Mar 25 |
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
|
Mar 7 |
Neuronetics Inc (STIM) Reports Record Revenues in Q4 and Full Year 2023
|
Mar 7 |
Neuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Neuronetics announces 5-year exclusive partnership with TCN
|